The p53 tumor suppressor is activated in response to various stresses driving the cells into growth arrest or apoptosis. We have addressed the question of how disintegration of microtubule system induces activation of p53. Depolymerization of microtubules by colcemid in rat and human quiescent ®broblasts resulted in accumulation of transcriptionally active p53 that caused cell-cycle arrest at the G1/S boundary. The p53 activation correlated with prominent activation of Erk1/2 MAP kinases that resulted from colcemid-stimulated development of focal adhesions. Inhibition of focal contacts development by plating of cells onto poly-L-lysine abrogated both Erk1/2 and p53 activations in colcemid-treated cells, while plating of cells onto ®bronectin caused transient up-regulation of p53 even in the absence of colcemid. Pre-treatment of cells with the speci®c MEK1 inhibitor PD098059 also attenuated colcemid-induced p53 activation and G1 cell cycle arrest. Cell types which either failed to develop focal adhesions in response to colcemid treatment (human MCF-7 epithelial cells), or lacked colcemid-induced sustained Erk activation (primary mouse embryo ®broblasts and 12(1) cells) showed virtually no p53 up-regulation in response to disruption of microtubules during G0/G1. Our results indicate that p53 activation is not triggered by disintegration of microtubule system by itself, but rather originates from some of the consequences of such disintegration, in particular, from the development of focal adhesions leading to activation of Erk signaling pathway. Oncogene (2001) 20, 899 ± 909.
Introduction p53 tumor-suppressor gene serves as a key component of a cellular emergency response mechanism that converts a variety of extra-and intra-cellular stress signals (such as DNA damage, metabolic de®ciencies, hypoxia, cytoskeleton disintegration, oncogene activation, etc.) into growth arrest or apoptosis (reviewed in Giaccia and Kastan, 1998; Gottlieb and Oren, 1996; Jimenez et al., 1999; Sherr, 1998) . In this way the p53 controls immediate elimination of genetically damaged and potentially dangerous cells. Abrogation of p53 function results in loss of growth restriction of cells with genomic abnormalities and/or activated oncogenes that helps to explain why loss of normal p53 activity is the most common molecular alteration in a variety of malignant diseases (Harris, 1996; Levine, 1997) . p53 is a transcription factor that up-regulates expression of a set of genes responsible for execution of checkpoints operating in G1 (p21
) and G2 (p21
, gadd45, 14-3-3d) and for induction of apoptosis (bax, fas, killer/DR5, IGF-BP3, cyclinG, PIG3 and others) (Ko and Prives, 1996; Amundson et al., 1998; el-Deiry, 1998; Prives and Hall, 1999; . In addition, p53 can down-regulate a number of genes involved in cell cycle progression, such as DP1 (Gopalkrishnan et al., 1998) , cyclin B1, cdc2 (Passalaris et al., 1999.) and regulation of apoptosis, such as bcl2 (Miyashita et al., 1994; Miyashita and Reed, 1995) .
Functional activation of p53 results from both accumulation and conformational changes within the protein. Multi-site phosphorylation/dephosphorylation seems to be a frequent mechanism by which p53 stability and conformation can be altered. In addition, other covalent modi®cations of p53 protein molecule as well as binding to speci®c p53-interacting proteins can contribute to p53 activation. Abrogation of Mdm2-mediated proteasome degradation of p53 is the major mechanism of p53 accumulation. Numerous observations indicate that N-terminal phosphorylation at sites in or around the Mdm2 binding region of p53 may increase p53 stability (reviewed in Prives, 1998; Ashcroft and Vousden, 1999; Prives and Hall, 1999) . Phosphorylation of Ser15 residue mediated by ATM, ATR, DNA-PK and phosphorylation at Ser20 by Chk1 and Chk2 are considered to be the most important events in p53 activation caused by DNA damage (Lakin and Jackson 1999; Chehab et al., 2000; Shieh et al., 2000) . In cells expressing oncogenes (ras, raf, myc, E1A) stabilization of p53 is controlled by E2F-mediated up-regulation of p19/p14
arf that interferes with p53 binding to Mdm2 (reviewed in Sherr, 1998; Ashcroft and Vousden 1999; . Binding of p53 to c-Abl also results in mitigation of Mdm2-mediated degradation . Along with stabilization of p53 molecule the above interactions can lead to secondary modi®cations within C-terminal regulatory domain that cause transition of p53 molecule from a latent to a transcriptionally active form (reviewed in Giaccia and Kastan, 1998, Lakin and Jackson, 1999; Prives and Hall, 1999) . Likewise, phosphorylation at Ser15 stimulates p300/CBP-mediated acetylation of Lys382 residue (Lambert et al., 1998) , and association with cAbl results in signi®cant increase in transcriptional activity of p53 (Nie et al., 2000) . ATM can promote dephosphorylation at Ser376 followed by covalent binding of 14-3-3 proteins and increase in transcriptional activity of p53 (Waterman et al., 1998) . Oncogenic ras stimulates p53 phosphorylation at Ser15 and acetylation at Lys382 via up-regulation of PML tumor-suppressor (Ferbeyre et al., 2000; Pearson et al., 2000) .
Despite signi®cant progress in understanding the mechanisms leading to activation of p53 pathway in response to some stresses, little is known about pathways mediating p53 activation following disintegration of cytoskeleton and alterations of cell-matrix interactions. The present study addresses the question how p53 function is controlled by the microtubule cytoskeleton integrity. The disruption of microtubules in rat and human (but not murine) interphase ®broblasts is accompanied by p53 accumulation and increase of its transcriptional activity followed by G0/ G1 cell cycle arrest. We found that colcemid-induced up-regulation of the integrin-Raf-MAP-kinase signaling cascade is most likely responsible for p53 activation in interphase cells with a disintegrated microtubule system.
Results
Microtubule disruption in G0/G1 cells activates p53 in human and rat, but not in murine fibroblasts
To assess the involvement of p53 in surveillance of microtubule system integrity we studied whether depolymerization of microtubules in interphase cell can aect p53 function. To obtain a uniform population of interphase cells the cell cultures were synchronized in G0/G1 by serum starvation for 72 h.
First we analysed how colcemid treatment of G0/G1 cells aects p53 content. Western blot analysis demonstrated clear increase of p53 levels in rat REF52 and human WI38 ®broblasts treated with colcemid for 24 h (Figure 1a) . Notably, this was accompanied by increase in proportion of p53 phosphorylated at Ser15 (Figure 1b ) that is characteristic of p53 activation in response to various stresses (Lakin and Jackson 1999; Prives and Hall, 1999; Chehab et al., 2000) . To investigate directly whether enhanced p53 levels in cells with disrupted microtubules correlate with higher p53 functional activity the REF52 cells were transiently transfected with the construct expressing the luciferase reporter gene under the control of p53 responsive p21 waf1 gene promoter. Signi®cantly higher luciferase expression was observed in synchronized cells treated with colcemid for 24 ± 48 h as compared with their untreated counterparts (Figure 1c ). Western blot analysis of p21 waf1
and Mdm2 protein expression Figure 1 Colcemid treatment of synchronized REF52 and WI38 cells leads to p53 accumulation and increase of its transcriptional activity. (a) REF52 and WI38 cells were synchronized in G0/G1 and 1.5 h after serum stimulation treated with colcemid (100 ng/ ml) for 24 h. Protein lysates were tested with anti-p53 (PAb421 for REF52 and PAb1801 for WI38) as well as with anti-hp21 and 2A10 antibodies, speci®c to p21 waf1 and Mdm2 proteins, respectively. (The experiment was repeated twice with similar results). (b) REF52 cells were synchronized in G0/G1 and 1.5 h after serum stimulation treated with colcemid (100 ng/ml, 24 h) or EMS (600 mg/ml, 6 h). Protein lysates were tested with anti-p53 (PAb421) or anti-phospho-Ser15. (The experiment was repeated twice with similar results). (c) REF52 cells were transiently cotransfected with the p21 waf1 -pWWp-GL2 construct expressing luciferase under the control of p53-responsive promoter and pCH100 plasmid (Pharmacia) expressing b-galactosidase. Then the cells were synchronized in serum-free medium. Colcemid (100 ng/ml) was added 1.5 h after serum stimulation. After incubation with colcemid for various periods of time the cells were lysed and luciferase assay was performed. To normalize the luciferase activity the b-galactosidase activity was measured in the same lysates. (Each point represents average data obtained from nine samples) con®rmed activation of p53 downstream genes in colcemid-treated REF52 and WI-38 ®broblasts ( Figure  1a ).
As expected, p53 induction in response to microtubule disruption in G0/G1 cells was followed by cell cycle arrest at the G0/G1-to-S boundary. In fact, very small portion of synchronized REF52 cells re-entered S phase in the presence of colcemid (Figure 2a) . Inactivation of p53 eliminated the G1/S phase arrest in cells with disrupted microtubules: more than a half of colcemid-treated REF52 cells expressing dominantnegative p53 mutant (His175) or dominant-negative Cterminal p53 genetic suppressor element (GSE) incorporated 5-BrdU (Figure 2b) . Thus, normal p53 function is required to prevent proliferation of cells with disrupted microtubule cytoskeleton.
Unexpectedly, similar mechanism was not found in all murine ®broblast cell lines tested. Western blot analysis revealed no p53 accumulation in presynchronized 12(1) cells after treatment with colcemid for 6 ± 24 h (Figure 3a) . Accordingly, the 12(1)Con cells bearing b-galactosidase reporter gene under control of a p53-responsive promoter did not show any increase in p53 transcriptional activity after disruption of microtubules in G0/G1 cells, although the same cells demonstrated p53 accumulation and functional activation after DNA damage (Figure 3a,b) . As a result the 12(1) cells and primary murine embryo ®broblasts (MEFs) presynchronized in G0/G1 readily entered S phase in the presence of colcemid (Figure 3c ), while the G0/G1-to-S transition in the same cells was eciently inhibited by a DNA damage (Figure 3c ). p53-mediated cell cycle arrest was observed in synchronized murine ®broblasts only after prolonged (more than 24 h) incubation with colcemid as had previously been found (Lanni and Jacks, 1998) . Almost certainly, the p53 activation in the above case was due to an increase in ploidy level (Lanni and Jacks, 1998) and/or formation of micronuclei (Sablina et al., 1998) . In agreement with this suggestion we found that unsynchronized 12(1) cell cultures, unlike those presynchronized at G0/G1, show gradual accumulation of p53 within 14 ± 24 h period after addition of colcemid ( Figure 3a) . Thus, the obtained data indicate that depolymerization of microtubule system in interphase cells causes immediate activation of p53 pathways in rat and human, but not in mouse ®broblasts.
MAP kinases play critical role in p53 activation in response to microtubule disruption
Previous studies have shown that microtubule disruption in ®broblasts induces signal transduction pathways similar to that triggered by cell attachment to the extracellular matrix (Bershadsky et al., 1996; Enomoto, 1996) . In particular, the data imply activation of MAP kinases in cells with impaired microtubule system, which in turn may directly or indirectly modulate p53 function. Indeed, the ability of Erk kinases to phosphorylate p53 protein at Ser15 (She et al., 2000) and aect its stability via p19 arf pathway (Lin et al., 1998; Ashcroft and Vousden, 1999) was reported. Based on these data we decided to test contribution of MAP kinases in modulating p53 activity in cells with disintegrated microtubule system.
We observed prominent increase of Erk1/2 phosphorylation in colcemidtreated rat (REF52) and human (WI38) ®broblasts (Figure 4a ), but not in murine ®broblasts (12(1) and NIH3T3) that lack p53 upregulation ( Figure 4b ). Noteworthy, other stresses that result p53 activation, such as g-irradiation (Levine, 1997; Lakin and Jackson, 1999) or disruption of actin micro®laments by cytochalasin D , did not cause Erk1/2 phosphorylation in REF52 cells (Figure 4a ). Pre-treatment of cells with the speci®c inhibitor of MEK1 (PD098059, 30 mM) abolished both Erk1/2 phosphorylation and p53 functional activation in response to colcemid treatment (Figure 5a ,b), but did not aect p53 transcriptional activation induced by DNA damage (data not shown). In agreement with Figure 2 Colcemid treatment of synchronized in G0/G1 REF52 cells leads to p53-dependent cell cycle arrest at G1/S boundary. (a) REF52 cells were synchronized in G0/G1 by incubation in serum-free medium for 72 h. Addition of colcemid (100 ng/ml) 1.5 h after serum stimulation caused inhibition of G0/G1 to S phase transition. (Abscissa -DNA content, ordinate ± the number of cells counted. The data of one of three typical experiments are shown). (b) REF52/neo, REF52/GSE22 and REF52/His175 cells were synchronized in G0/G1. 1.5 h after serum stimulation cells were treated with colcemid (100 ng/ml). 1.5 h later the cells were pulse labeled with 5-BrdU for additional 14 h. 5-BrdU incorporation was determined by immunostaining. (In each case 500 cells were analysed; the experiment was repeated twice with similar results)
Figure 3 G0/G1 murine ®broblasts show no p53 accumulation (a), transcriptional activation (b) and G0/G1 cell cycle arrest (c) in response to colcemid treatment. (a) Unsynchronized 12(1) cells growing in the medium containing 10% FCS were treated with colcemid (100 ng/ml) for 14 or 24 h. Other 12(1) cells were synchronized by incubation in serum-free medium for 72 h. 1.5 h after serum stimulation the cells were treated with colcemid (100 ng/ml, 14 ± 24 h) or g-irradiated (6 Gy). (The data of one of three typical experiments are shown). (b) 12(1) cells were synchronized in G0/G1. 1.5 h after serum stimulation the cells were treated with colcemid (100 ng/ml) or ethyl metane sulphonate (EMS, 600 mg/ml) for 24 h. Then analysis of p53-dependent b-galactosidase expression was performed. (In each case more than 500 cells were analysed). (c) Cells were synchronized in G0/G1. 1.5 h after serum stimulation colcemid (100 ng/ml) or EMS (600 mg/ml) was added. 1.5 h later the cells were pulsed with 5-BrdU for additional 14 h. 5-BrdU incorporation was determined by immunostaining. (In each case 500 cells were analysed; the experiment was repeated twice with similar results) these data Western blot analysis revealed that pretreatment with PD098059 inhibited accumulation of p21 waf1 in cells with disrupted microtubules (Figure 5c ) and partially attenuated colcemid-induced inhibition of G0/G1-to-S transition (data not shown). Taken together, these data suggest that MAPK pathway mediates p53 activation in response to microtubule depolymerization in human and rat ®broblasts.
Assembly of focal adhesions is essential for mediating p53 activation in cells with disrupted microtubules
Recent data indicate that microtubules exert negative eect on development of focal contacts (Kaverina et al., 1998) . Thus, microtubule disruption in ®broblasts leads to dramatic growth of focal adhesions, which in turn leads to colcemid-induced MAPK activation (Bershadsky et al., 1996; Enomoto, 1996) .
To test whether focal adhesions and integrin signaling play a critical role in p53 activation upon disintegration of microtubule system the cells were plated onto plastic coated with poly-L-lysine, thus allowing the cells to attach independently of integrin activation (Bershadsky et al., 1996) . Immunostaining for vinculin con®rmed that colcemid treatment increase the number and the size of focal adhesion contacts in control cells while only dot-like focal adhesions were observed in colcemid-treated cells plated onto poly-Llysine (Figure 6a ). Development of focal adhesions after addition of colcemid was accompanied by signi®cant increase in the quantity of proteins containing phosphotyrosine (Figure 6b ) and Erk1/2 phosphorylation in control cells, but not in poly-L-lysine-plated cells (Figure 7a ). Thus, plating onto poly-L-lysine abrogated activation of integrin-MAPK pathway in cells with disrupted microtubules.
Immuno¯uorescence analysis revealed that colcemid treatment resulted in approximately fourfold increase in the number of p53-positive cells in control cultures, while in colcemid-treated cultures plated onto poly-Llysine no augmentation in the number of p53-positive cells was observed (Figure 7b ). In agreement with these data, analysis of p53-responsive luciferase gene expression indicated that addition of colcemid to poly-Llysine-plated cells did not increase transcriptional (1) and NIH3T3 cells showed no increase in phospho-Erk1/2 expression after treatment with colcemid (100 ng/ml, 6 h) (The experiment was repeated twice with similar results) (Figure 7d ).
Unlike ®broblasts, depolymerization of microtubules in epithelium cells does not lead to the focal adhesion assembly (Pletjushkina et al., 1998) . Therefore, it was interesting to test whether microtubule disruption can activate p53 in quiescent epithelial cells. For this purpose the MCF7 cells originating from human breast epithelium were used. When pre-synchronized at G0/G1 the MCF7 cells showed neither development of focal adhesions (Figure 8a ), nor Erk1/2 phosphorylation in the presence of colcemid (Figure 8b ). Western blot analysis demonstrated no increase of p53 content in response to colcemid treatment, while g-irradiation caused prominent p53 accumulation (Figure 8c) . Thus, the data obtained with epithelial cells support the idea that in cells with disrupted microtubules development of focal adhesions mediates p53 activation through the integrin-MAPK (Erk1/2) pathway.
In agreement with the above idea we observed p53 activation 18 h after plating of REF52 or HEF/ConA cells onto ®bronectin as opposed with their counterparts plated onto plastic or poly-L-lysine (Figure 9 ). However, while in ®bronectin-plated cells the reporter gene activity returned to the control level 36 h after cell plating, there was no reduction of p53 transcriptional activity during prolonged treatment with colcemid ( Figure 9) . Evidently, there can be additional factors that sustain p53 up-regulation in cells with disrupted microtubules.
Discussion
In this study we have addressed the question whether p53 can be involved in surveillance of integrity of microtubule cytoskeleton. Earlier Lanni and Jacks (1998) demonstrated that in mouse NIH3T3 cells treated with nocodazole p53-mediated G1 arrest occurs only in cells with 4 n DNA content, but not in diploid cells. That was consistent with the idea that increased ploidy level resulted from chromosome non-disjunction during mitosis rather than disintegration of microtubule system activates p53 function. In the present study we found that unlike in mouse cells disruption of microtubules in quiescent ®broblasts of rat or human results in p53 accumulation and transcriptional activation within 12 ± 24 h, followed by cell cycle arrest at the G1-to-S boundary. Notably, this eect was observed in low-passage human embryo ®broblasts and nonimmortalized WI38 lung ®broblasts suggesting its relation to normal cell physiology. Using a similar approach Khan and Wahl (1998) observed G1 cell cycle arrest in nocodazole-treated synchronized normal human ®broblasts with 2 n DNA content but not in their isogenic p53-de®cient derivatives. Taken together these data indicate that at least in some cell contexts activation of p53 in response to microtubule depolymerization does not require entrance of the cell to mitosis followed by its abnormal completion, i.e. chromosome non-disjunction (Lanni and Jacks, 1998) and/or micronuclei formation which were shown to activate p53 (Sablina et al., 1998) .
It was established previously that microtubulemodifying agents are capable to activate the Raf-MAP-kinase pathways (Wang et al., 1999) . On the other hand, MAPK signaling was shown to mediate p53 up-regulation in response to permanent expression of ras oncogene (Lin et al., 1998) , as well as UVirradiation (She et al., 2000) and taxol treatment (Blagosklonny et al., 1995) . Therefore, in order to identify pathways mediating p53 activation in response to disruption of microtubules in interphase cells we studied its dependence on MAP kinase signaling. We found that in resting rat and human ®broblasts colcemid treatment induced phosphorylation of Erks and that pre-treatment of cells with speci®c MEK1 inhibitor PD098059 attenuated both Erk1/2 phosphor- -pWWp-GL2 pCH100 constructs as described in Figure 1c . Plating onto poly-L-lysine abrogated colcemid-induced increase of the luciferase expression. (Each point represents average data obtained from nine samples). (d) REF52 cells were synchronized in G0/G1 by incubation in serum-free medium for 72 h. Addition of colcemid (100 ng/ml) 1.5 h after serum stimulation caused inhibition of G0/ G1 to S phase transition. Plating onto poly-L-lysine signi®cantly relieved the arrest of G0/G1 to S phase transition. (Abscissa -DNA content, ordinate ± the number of cells counted. The data of one of three typical experiments are shown) our previous observation that dominant-negative Raf-C4 mutant, similar to the MEK1 inhibitor, prevented colcemid-induced G1 cell cycle arrest in rat cells , strongly indicate a critical role of Raf-MEK1-Erk pathway in mediating p53 activation in response to disintegration of microtubule system.
One of the triggers for MAPK pathway activation in response to microtubule disruption could be development of mature focal adhesions. Indeed, treatment of ®broblasts with colcemid or nocodazole was shown to induce an increase in the number and size of focal adhesions accompanied by activation of FAK kinase and MAPK (Bershadsky et al., 1996; Wang et al., 1999) . To assess the role of integrin signaling in colcemid-induced p53 up-regulation we used plating onto poly-L-lysine substrate that promotes attachments of cells to the surface by integrin-independent manner. We have found that such plating prevented accumulation and transcriptional activation of p53 and signi®cantly relieved inhibition of G0/G1 to S phase transition in cells with disrupted microtubules. In accordance with this observation MCF-7 epithelial cells that showed no development of focal adhesions in response to microtubule disruption demonstrated no colcemid-induced activation of p53. These results suggest that development of mature focal adhesions can be a trigger for p53 up-regulation in human and rat ®broblasts with disintegrated microtubule system.
To verify the role of focal adhesions in p53 induction we studied whether plating onto ®bronectin-coated substrates can also lead to an increase in p53 transcriptional activity. We observed temporal upregulation of p53 in cells plated onto ®bronectin as compared with cells plated onto plastic or poly-Llysine. The eect was transient: 18 h after plating onto ®bronectin the cells showed higher reporter gene activity, but by 36 h the activity went down. Along with recent observations showing induction of p53-mediated apoptosis in response to expression of alpha 6 beta 4 in carcinoma cells which lack this integrin (Bachelder et al., 1999) our results support the idea that activation of integrin-ERK pathways can trigger, at least in some cell contexts, p53 up-regulation. It should be noted, however, that while activation of p53 following ®bronectin plating was transient, disruption of microtubules caused sustained activation of p53 that was observed during all the period of treatment with colcemid. Thus, in cells with disintegrated microtubule system there could be additional factors that maintain p53 up-regulation in response to development of focal adhesions.
We also found that development of focal adhesions is necessary but not sucient for activation of p53 in response to microtubule disruption. Indeed, all tested murine ®broblasts showed no p53 activation, although we (data not shown) and others (Bershadsky et al., 1996; Enomoto, 1996) observed colcemid-induced increase of focal adhesions. The observed failure of mouse cells to show p53 activation was not due to p19 arf mutations in these cells because primary MEFs are wild type for this gene. Distinct p53 responses in human and rat versus mouse cells may re¯ect the dierences in kinetics of integrin-induced Erk upregulation in these cells. Indeed, 3 ± 24 h after application of colcemid we observed prominent activation of Erks in human and rat, but not in mouse ®broblasts. It has been reported earlier (Howe and Juliano, 1998; Schlaepfer et al., 1998) that in mouse NIH3T3 cells ®bronectin-stimulated Erk activation is observed only during a short period (10 ± 120 min after adhesion). One can propose that sustained Erk activation for the period longer than 2 h is required to induce p53 upregulation. Certainly, we cannot exclude the possibility that along with the requirement for prolonged integrinErk signaling some additional factors are necessary to induce p53 activation in cells with disrupted microtubules.
Taken together our results indicate that disintegration of microtubule system triggers p53 activation through the MAPK pathway. The described earlier activation of p53 in response to increase in ploidy level (Lanni and Jacks, 1998) and formation of micronuclei (Sablina et al., 1998) was observed only after abnormal completion of mitosis due to spindle dysfunction. The Figure 8 Colcemid-treated MCF-7 cells show neither development of focal adhesions as revealed by vinculin staining (a), nor Erk1/2 phosphorylation (b), nor p53 up-regulation (c). Colcemid (100 ng/ml) was added for 6 h in the case of vinculin staining and Erk1/2 analysis and for 24 h in the case of p53 detection. Unlike colcemid treatment, g-irradiation (6 Gy) induced p53 accumulation in G0/G1 MCF-7 cells present study shows that in interphase cells depolymeryzation of microtubules can trigger p53 activation through development of focal adhesions. This type of p53 activation occurs more rapidly, but is not observed in murine cells. The revealed activation of p53 in response to sustained integrin-Erk signaling represents further demonstration of the central role that p53 might play in controlling orderly fashion of events that are required for proper processing through the cell cycle. However, the detailed mechanisms by which integrin-MAPK signaling induces p53 up-regulation remain to be elucidated.
Materials and methods

Cell cultures
The following p53-positive cell cultures were used: (i) mouse embryo ®broblasts at 2 ± 5 passage; (ii) NIH3T3 murine immortalized ®broblasts (Rittling and Denhardt, 1992) ; (iii) 12(1) murine immortalized ®broblasts (Harvey and Levine, 1991) and their subline 12(1)Con expressing bacterial bgalactosidase under the control of p53-responsive promoter (Komarova et al., 1997) , was kindly provided to us by Dr GR Stark, Cleveland Clinic Foundation, Cleveland]; (iv) spontaneously immortalized REF52 rat ®broblasts (Ishizaka et al., 1995) and their subline obtained by transfection with the insert-free pPS-neo vector [REF52/neo cell line ]; (v) normal human embryo ®broblasts with p53-dependent expression of b-galactosidase gene due to introduction of pSIP-ConA-LacZ-puro self-inactivating retroviral construct (S Strunina and P Chumakov, unpublished) that underwent approximately 10 ± 12 cell doublings ex vivo (HEF/ConA-lacZ cells); (vi) WI38 normal human lung ®broblasts; and, (vi) MCF7 human breast carcinoma cell line. REF52 derivatives in which p53 function was inhibited by transduction of dominant-negative human mutant p53-His175 [REF52/175 subline ] or rat p53 C-terminal fragment (Ossovskaya et al., 1996) [REF52/GSE cell line (Sablina et al., 1998) ] were also used.
All cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (Gibco Booklet, Scotland) in a humidi®ed atmosphere supplied with 5% CO 2 .
Plating onto poly-L-lysine-and fibronectin-coated surfaces
To obtain poly-L-lysine coated surfaces plastic culture dishes were incubated for 10 min with 0.1% aqueous solution of poly-L-lysine (Sigma), rinsed with water and allowed to dry for 2 ± 3 h. For ®bronectin coating the surfaces were treated ®rst with poly-L-lysine and then incubated for 10 min with a 0.1 mg/ml solution of bovine plasma ®bronectin (Sigma), rinsed with PBS and sterilized by UV-irradiation.
Analysis of G0/G1-to-S transition was performed using cell cultures previously synchronized in G0
For this purpose cells were washed twice with Hanks solution for 10 ± 15 min and placed into a serum-free DMEM medium for 72 h. Re-entry into cell cycle was initiated by addition of the medium containing 10% fetal bovine serum. One and a half hours later colcemid (Sigma, 100 ng/ml) or ethyl metane-sulfonate (EMS, Serva, 600 mg/ ml) were added to the culture medium. Ability of cells to enter S phase was studied by FACScaning and by analysis of 5-BrdU incorporation.
For FACScan analysis the cells were trypsinized 24 h after serum addition, ®xed with cold ethanol for 1 h and incubated in the solution containing 50 mg/ml of propidium iodide, and 100 mg/ml of RNAse A. Analysis was performed using a Becton-Dickinson FACSCAN and Cell®t (Becton-Dickinson) software. For analysis of 5-BrdU incorporation 1.5 h after colcemid or EMS addition 5-BrdU (10 75 M) was added to the culture medium for 14 h. After incubation with 5-BrdU the cells were washed 2 ± 3 times with PBS, ®xed with 70% ethanol and incubated in the solution of 2M HCl and 0.5% Triton X-100 at room temperature for 2 h. 5-BrdU incorporation was revealed by indirect immunostaining with BU-33 monoclonal antibody speci®c to 5-BrdU (Sigma) and TRITC-conjugated anti-mouse IgG (Sigma).
Expression of p53, p21
waf1 and Mdm2 proteins
Whole cells extracts were lysed in RIPA buer. Concentration of protein in extracts was determined using BioRad protein assay system. One hundred mg of protein was resolved on a 10% SDS polyacrylamide gel and transferred to PVDF membrane (Millipore). The membranes were probed with monoclonal antibodies speci®c to p53 (PAb421, PAb246 and PAb1801) or p53 phosphorylated at Ser15 (anti-phospho-Ser15 antibodies kindly provided by Dr Y Taya, National Cancer Center Research Institute, Tokyo, Japan), Mdm2 (2A10) and rabbit polyclonal antibodies to p21 waf1 (anti-hp21). The membranes were treated with secondary sheep anti-mouse-HPR or anti-rabbit-HPR antibodies (Jackson Immunoresearch Lab). Detection was done by ECL chemiluminescence reagents (Dupont NEN) according to manufacturer's protocol.
For immuno¯uorescence analysis of p53 expression cells were ®xed with methanol/acetone (1 : 1). Then methanol/ acetone was gradually replaced with PBS and the cells were stained with PAb421 monoclonal antibodies speci®c to p53. PAb421/p53 complexes were visualized by indirect staining with Biotin-conjugated anti-mouse IgG and FITC-labeled Streptavidin (both Jackson Immunoresearch Lab).
p53 trans-activational function
For luciferase assay cells were transiently transfected using lipofectaAMINE reagent (Gibco ± BRL) with 1 mg of the pWWp-GL2 construct expressing luciferase under the control of wild-type p21 waf1 gene promoter (Buckbinder et al., 1994) . To control the eciency of transfection the cells were cotransfected with 0.5 mg of plasmid pCH100 (Pharmacia) expressing b-galactosidase. Luciferase assay was performed using Dual-Light luminescent reporter gene assay system (Tropix).
b-galactosidase staining of 12(1)Con cells was performed as described previously (Sablina et al., 1998) . For quantitative bgalactosidase assay the cells were harvested by scarping in 0.1 M sodium phosphate (pH 7.5) and subjected to three cycles of freezing and thawing. Protein concentration of lysates was determined using BioRad protein assay system. The extracts with similar protein content were incubated with o-nitrophenyl-b-D-galactopyranoside (0.88 mg/ml), mercaptoethanol (45 mM) and MgCl 2 (1 mM) at 378C for 4 h as described elsewhere. Reactions were stopped by addition of 1 M Na 2 CO 3 and absorbency of b-galactosidase color reaction product was detected by spectrophotometry at 420 nm.
Erk1/2 phosphorylation
Cells were cultured overnight in serum-free medium, treated with 100 ng/ml colcemid for 6 h and lysed (each sample was prepared using 4610 5 cells). Western immunoblotting was performed using E10 phospho-p44/42 MAP kinase (Thr202/ Tyr204) monoclonal antibody (New England Biolabs) according to manufacturer's protocol.
Phosphotyrosine level was determined by probing of cell lysates with anti-phospho-tyrosine antibodies Ab-4 (Oncogene Research).
Analysis of focal adhesions
For vinculin immunostaining the cells were permeabiliazed by brief treatment with 0.5% Triton X-100 in 50 mM MES buer (pH 6.0) and ®xed with 4% paraformaldehyde for 15 min. Vinculin was revealed by indirect immunostaining with mouse hVin-1 monoclonal antibody (Sigma) and FITC-conjugated anti-mouse IgG (Jackson Immunoresearch Lab.).
